EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation

Brooks D Cash, Amol Sharma iD, Anna Walker, Adam P Laitman, Lin Chang iD

Neurogastroenterology & Motility · 2023-09 · 35 (9)

DOI: 10.1111/nmo.14632 ↗

At a glance

Randomisierte kontrollierte Studie in Neurogastroenterology & Motility, published online on 2023-06-18. Written by Brooks D Cash and 4 co-authors. Institution: Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA. Major MEDLINE topics: Irritable Bowel Syndrome. Cited 12 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: Salix Pharmaceuticals, Synergy Pharmaceuticals.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS‐C) often experience severe symptoms. The current aim was to evaluate plecanatide in adults with CIC or IBS‐C with severe constipation.

Methods

Data were analyzed post hoc from randomized, placebo‐controlled trials (CIC [ n = 2], IBS‐C [ n = 2]) of plecanatide 3 mg, 6 mg, or placebo administered for 12 weeks. Severe constipation was defined as no complete spontaneous bowel movements (CSBMs) and an average straining score ≥3.0 (CIC; 5‐point scale) or ≥8.0 (IBS‐C; 11‐point scale) during a 2‐week screening. Primary efficacy endpoints were durable overall CSBM responders (CIC: ≥3 CSBMs/week, plus increase from baseline of ≥1 CSBM/week, for ≥9 of 12 weeks, including ≥3 of the last 4 weeks) and overall responders (IBS‐C: ≥30% reduction from baseline in abdominal pain and ≥1 CSBM/week increase for ≥6 of 12 weeks). Key Results Severe constipation was observed in 24.5% (646/2639) and 24.2% (527/2176) of CIC and IBS‐C populations, respectively. The CIC durable overall CSBM response rate (plecanatide 3 mg, 20.9%; plecanatide 6 mg, 20.2%; placebo, 11.3%) and IBS‐C overall response rate (plecanatide 3 mg, 33.0%; plecanatide 6 mg, 31.0%; placebo, 19.0%) were significantly greater with plecanatide versus placebo ( p ≤ 0.01 for all). Median time to first CSBM in CIC and IBS‐C populations were significantly shorter with plecanatide 3 mg versus placebo ( p = 0.01 for both). Conclusions and Inferences Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS‐C.

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeHumansAdultPeptidesConstipationNatriuretic PeptidesTreatment OutcomeDouble-Blind Method

Author keywords

Trulanceconstipationguanylyl cyclase C agonistsirritable bowel syndromeplecanatide

Substances

plecanatidePeptidesNatriuretic Peptides

Authors and institutions

  • Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA.
  • Division of Gastroenterology & Hepatology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Salix Pharmaceuticals, Bridgewater, New Jersey, USA.
  • Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.

ORCID profiles: Amol Sharma, Lin Chang

Funding

  • Salix Pharmaceuticals
  • Synergy Pharmaceuticals

Cite

APA

Cash, B. D., Sharma, A., Walker, A., Laitman, A. P., & Chang, L. (2023). Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility, 35(9). https://doi.org/10.1111/nmo.14632

Vancouver

Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility. 2023;35(9). doi:10.1111/nmo.14632

BibTeX
@article{Cash2023,
  author = {Cash, Brooks D and Sharma, Amol and Walker, Anna and Laitman, Adam P and Chang, Lin},
  title = {Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  volume = {35},
  number = {9},
  doi = {10.1111/nmo.14632}
}
Start for free →